PubMed Health⌕ Search

PubMed · 15738725

Primary sclerosing cholangitis: a case presentation.

Abstract

Liver function tests are elevated in a variety of settings and with a mild elevation, it is difficult to decipher the cause. Typical causes of elevated liver enzymes may range from hepatocellular injury such as hepatitis C, to obstructive causes, such as primary sclerosing cholangitis. Primary sclerosing cholangitis is known to be associated with inflammatory bowel disease and may be more common than once thought.This article presents case study of a patient who presented with mildly elevated liver function tests and intermittent diarrhea. The patient was diagnosed with Crohn's disease and primary sclerosing cholangitis. The patient's presentation and the relation of inflammatory bowel disease and primary sclerosing cholangitis will be discussed. The importance of early detection of primary sclerosing cholangitis in an effort to decrease the morbidity and mortality from cholangiocarcinoma will also be emphasized. An overview of various diagnostic testing needed to make the diagnosis, as well as treatment modalities of both Crohn's disease and primary sclerosing cholangitis will also be presented.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gabriella Der, Tiffany Love, Jennifer Schreck, Mitzi Horn. Primary sclerosing cholangitis: a case presentation.. https://doi.org/10.1097/00001610-200501000-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗